HRP970410A2 - Butyric acid matrix metalloproteinase inhibitors - Google Patents

Butyric acid matrix metalloproteinase inhibitors

Info

Publication number
HRP970410A2
HRP970410A2 HR60/024,025A HRP970410A HRP970410A2 HR P970410 A2 HRP970410 A2 HR P970410A2 HR P970410 A HRP970410 A HR P970410A HR P970410 A2 HRP970410 A2 HR P970410A2
Authority
HR
Croatia
Prior art keywords
oxo
butyric acid
dibenzofuran
compound
amino
Prior art date
Application number
HR60/024,025A
Other languages
English (en)
Croatian (hr)
Inventor
Joseph Armant Picard
Original Assignee
Joseph Armant Picard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joseph Armant Picard filed Critical Joseph Armant Picard
Publication of HRP970410A2 publication Critical patent/HRP970410A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91Dibenzofurans; Hydrogenated dibenzofurans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR60/024,025A 1996-08-16 1997-07-23 Butyric acid matrix metalloproteinase inhibitors HRP970410A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2402596P 1996-08-16 1996-08-16

Publications (1)

Publication Number Publication Date
HRP970410A2 true HRP970410A2 (en) 1998-08-31

Family

ID=21818459

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/024,025A HRP970410A2 (en) 1996-08-16 1997-07-23 Butyric acid matrix metalloproteinase inhibitors

Country Status (11)

Country Link
US (1) US6020366A (ja)
EP (1) EP0923569B1 (ja)
JP (1) JP2000516607A (ja)
AT (1) ATE282602T1 (ja)
AU (1) AU3729397A (ja)
CO (1) CO4900041A1 (ja)
DE (1) DE69731642T2 (ja)
ES (1) ES2231879T3 (ja)
HR (1) HRP970410A2 (ja)
WO (1) WO1998006711A1 (ja)
ZA (1) ZA977328B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516607A (ja) * 1996-08-16 2000-12-12 ワーナー―ランバート・コンパニー 酪酸マトリックスメタロプロテイナーゼ阻害剤
HUP0102714A3 (en) 1998-07-30 2003-01-28 Warner Lambert Co Tricyclic sulfonamid derivatives as inhibitors of matrix metalloproteinases and medicaments containing the same
AU4229499A (en) 1998-07-30 2000-02-21 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
US7325009B1 (en) 2000-06-30 2008-01-29 Brightpoint, Inc. Customer-controlled inventory access
JP2006516252A (ja) * 2002-12-27 2006-06-29 アンジオテック インターナショナル アクツィエン ゲゼルシャフト コラーゲンおよびmmpiを用いる組成物および方法
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54551B1 (en) * 1982-01-22 1989-11-22 Ici Plc Amide derivatives
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
CN1151157A (zh) * 1994-06-22 1997-06-04 英国生物技术药物有限公司 金属蛋白酶抑制剂
US5665764A (en) * 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
JP2000516607A (ja) * 1996-08-16 2000-12-12 ワーナー―ランバート・コンパニー 酪酸マトリックスメタロプロテイナーゼ阻害剤

Also Published As

Publication number Publication date
ES2231879T3 (es) 2005-05-16
EP0923569B1 (en) 2004-11-17
CO4900041A1 (es) 2000-03-27
DE69731642D1 (de) 2004-12-23
ZA977328B (en) 1998-02-19
WO1998006711A1 (en) 1998-02-19
DE69731642T2 (de) 2005-12-01
US6020366A (en) 2000-02-01
EP0923569A1 (en) 1999-06-23
AU3729397A (en) 1998-03-06
JP2000516607A (ja) 2000-12-12
ATE282602T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
EP0934267B1 (en) Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
ES2250591T3 (es) Derivados de heteroarilo sustituidos con diacidos como inhibidores de metaloproteinasas de la matriz.
RU2059637C1 (ru) Гетероциклические производные замещенных 2-ациламино-5-тиазолов, способы их получения, производное замещенного 2-аминотиазола, производные 2-амино-4-фенилтиазола
KR100438633B1 (ko) N-(3-벤조푸라닐)우레아 유도체
AU700725B2 (en) Matrix metalloprotease inhibitors
EP0512570B1 (en) Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
EP0901466B1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
EP1212317B1 (en) Indole derivatives and their use for the treatment of osteoporosis amongst other applications
AU8270898A (en) Antithrombotic agents
MXPA03006598A (es) Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz.
AU8237698A (en) Acyclic metalloprotease inhibitors
CZ36899A3 (cs) Deriváty hydroxamové a karboxylové kyseliny a jejich použití
CA2375920A1 (en) Compounds
CZ211596A3 (cs) Inhibitory metaloproteázy, způsob jejich výroby, jejich použití a farmaceutické prostředky s jejich obsahem
JP2003528079A (ja) 複素環式側鎖含有メタロプロテアーゼ阻害剤
EP0769498A1 (en) Sulfonamide derivatives with elastase inhibiting activity
AU9788298A (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
EP0923569B1 (en) Butyric acid matrix metalloproteinase inhibitors
JP2002542228A (ja) Mmp阻害剤
PL198827B1 (pl) ω-Amidy N-arylosulfonyloaminokwasów, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie ω-amidów N-arylosulfonyloaminokwasów
EP2955173B1 (en) 1,2-bis-sulfonamide derivatives as chemokine receptor modulators
ES2222711T3 (es) Derivados de acido hidroxamico como inhibidores de la produccion de cd23 humano y de la liberacion de tnf.
CA1295333C (en) Acylaminoalkanoyl compounds
EP1270569A1 (en) Substituted tryptophan derivatives
KR100242266B1 (ko) 캄포 구조를 갖는 신규한 트롬빈 억제제

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBC Application rejected